
|Articles|April 16, 2015
- Melanoma (Issue 4)
- Volume 4
- Issue 1
The Development of T-VEC for Melanoma
Author(s)Kevin B. Kim, MD
Kevin B. Kim, MD, medical oncology, California Pacific Medical Center, discusses the outlook for T-VEC for the treatment of patients with melanoma.
Advertisement
Kevin B. Kim, MD, medical oncology, California Pacific Medical Center, discusses the outlook for T-VEC for the treatment of patients with melanoma.
<<<
Articles in this issue
over 10 years ago
Toxicity of Immunotherapies in Melanomaover 10 years ago
Comparing Two Doses of Ipilimumabover 10 years ago
New Standards Needed to Lessen Surgery Delays in Melanomaover 10 years ago
Gene Removal May Pose Future Treatment in Advanced Melanomaover 10 years ago
The Role of Macrophages in BRAF Inhibitor ResistanceAdvertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Gedatolisib Improves PFS in HR+/HER2-/PIK3CA-WT Advanced Breast Cancer
2
Nadunolimab Misses Efficacy Mark in TNBC, Despite Strong OS
3
FDA Approves Niraparib/Abiraterone Combo for BRCA2-Mutated mCSPC
4
Real-World Pola-R-CHP vs R-CHOP Effectiveness in Older DLBCL Patients
5









































